DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR STALEVO 200

« Back to Dashboard

Clinical Trials for Stalevo 200

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00099268	Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy	Completed	Orion Corporation, Orion Pharma	Phase 3	The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
NCT00099268	Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy	Completed	Novartis Pharmaceuticals	Phase 3	The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
NCT00125567	Stalevo in Early Wearing-Off Patients	Completed	Orion Corporation, Orion Pharma	Phase 4	The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.
NCT00134966	A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa	Completed	Novartis	Phase 3	The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).
NCT00200447	An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)	Completed	Molecular NeuroImaging	Phase 2	This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses [123I]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

Clinical Trial Conditions for Stalevo 200

Condition Name

Condition Name for Stalevo 200
Intervention	Trials
Parkinson's Disease	11
Parkinson Disease	2
Idiopathic Parkinson's Disease	1
Sleep Disorders	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Stalevo 200
Intervention	Trials
Parkinson Disease	15
Parasomnias	1
Narcolepsy	1
Disease	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Stalevo 200

Trials by Country

Trials by Country for Stalevo 200
Location	Trials
United States	37
Italy	11
Canada	11
United Kingdom	7
Finland	7

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Stalevo 200
Location	Trials
Michigan	3
California	3
Florida	3
Texas	2
Rhode Island	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Stalevo 200

Clinical Trial Phase

Clinical Trial Phase for Stalevo 200
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Stalevo 200
Clinical Trial Phase	Trials
Completed	12
Recruiting	2
Terminated	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Stalevo 200

Sponsor Name

Sponsor Name for Stalevo 200
Sponsor	Trials
Orion Corporation, Orion Pharma	10
Novartis Pharmaceuticals	2
Molecular NeuroImaging	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Stalevo 200
Sponsor	Trials
Industry	14
Other	4

Export unavailable in trial.
Subscribe for complete access.